Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients
- Dennis CY Yeung, BSc1,4,
- Aimin Xu, PhD1,2,4,
- Annette WK Tso, MD1,4,
- WS Chow, MD1,
- Nelson MS Wat, MD1,
- Carol HY Fong, BSc1,
- Sidney Tam, MD5,
- Pak C Sham, MD3 and
- Karen SL Lam, MD (ksllam{at}hkucc.hku.hk)1,4
- Departments of 1Medicine
- 2Pharmacology and
- 3Psychiatry, and
- 4Research Centre of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, University of Hong Kong, and
- 5Clinical Biochemistry Unit, Queen Mary Hospital, HKSAR, China
Abstract
Objective: To investigate the relationship of serum adipocyte-fatty acid-binding protein (A-FABP) and epidermal-fatty acid binding protein (E-FABP) with renal dysfunction and macrovascular complications in type 2 diabetic patients.
Research design and methods: The associations of serum A-FABP and E-FABP with markers of renal function, nephropathy staging and macrovascular complications were examined in 237 type 2 diabetic patients.
Results: Serum A-FABP and E-FABP correlated significantly with serum creatinine, mean albumin excretion rate and glomerular filtration rate (all P < 0.001), and were independently associated with diabetic nephropathy staging (P = 0.001 and P < 0.05 respectively). Circulating levels of both FABPs were increased (P < 0.01) in subjects with macrovascular complications. Serum A-FABP was independently associated with macrovascular complications (OR: 2.92; 95% CI: 1.42 – 6.01, P = 0.004).
Conclusions: Serum A-FABP and E-FABP might be novel serum biomarkers for evaluating the progression of nephropathy and its cardiovascular risk in diabetic patients.
Footnotes
-
- Received July 18, 2008.
- Accepted October 8, 2008.
- Copyright © American Diabetes Association
